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Type: Commentary 1 
Modeling in Early Stages of Technology Development: Is an iterative approach 2 
needed? 3 
&RPPHQWRQ³3UREOHPVDQG3URPLVHVRI+HDOWK7HFKQRORJLHV7KH5ROHRI(DUO\4 
Health (FRQRPLF0RGHOLQJ´ 5 
Abstract 6 
A recent paper by Grutters et al makes the case for early health economic modeling in 7 
the development of health technologies. A number of examples of the value of early 8 
modeling are given, with analyses being performed at different stages in the 9 
development of several non-drug health technologies. This commentary 10 
acknowledges the contribution of the paper by Grutters et al and argues for an 11 
iterative and integrated approach to early modeling, assessing the cost-effectiveness 12 
of the technology, the value of future research and the interaction with the 13 
PDQXIDFWXUHU¶VSULFLQJDQGUHYHQXHH[SHFWDWLRQV 14 
 15 
Key words: innovation policy, innovation, health technology assessment, health 16 
economic modeling, early assessment. 17 
 18 
Introduction 19 
In their recent paper, Grutters et al (1) discuss the role of early health economic 20 
modeling in making key decisions in the development of health technologies. Their 21 
observations are based on 32 early modeling analyses of non-drug technologies 22 
undertaken by a subsidiary group of a university hospital in the Netherlands. The 23 
analyses were all conducted as a result of requests from technology sponsors, the 24 
majority of which were medical devices companies, although 3 analyses were 25 
conducted following requests by clinicians and/or clinical departments from the 26 
hospital.   27 
The modeling analyses were performed at different stages in the development of the 28 
WHFKQRORJLHV IURP µLGHD VFUHHQLQJ¶ WKURXJK µFRQFHSW GHYHORSPHQW¶ WR WKH µSUH-29 
PDUNHW SKDVH¶ WR µPDUNHW DFFHVV¶ The authors note that some researchers may not 30 
consider the final phase WRFRQVWLWXWHµHDUO\PRGHOLQJ¶, but I accept their view that this 31 
stage still precedes any formal modeling presented to authorities in an official 32 
reimbursement submission. The main finding is that none of the assessments resulted 33 
LQ D ILUP µJRQR-JR¶ GHFLVLRQ DERXW WKH WHFKQRORJLHV FRQFHUQHG VLQFH QRQH34 
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demonstrated that the technology could never be cost-effective. However, the 1 
assessments were helpful in gaining an insight into the WHFKQRORJ\¶V SRWHQWLDO FRVW-2 
effectiveness in its intended context by informing further development or 3 
implementation. These insights could include the positioning of the technology (eg 4 
position in the clinical pathway, of suitability for different patient sub-groups), or the 5 
need for additional research. 6 
Therefore are two, interlinked, modeling efforts that could be performed. The first is 7 
the modeling of the potential cost-effectiveness of the product, viewed from the 8 
perspective of the external decision-maker(s) that will partly determine the market 9 
access for the technology. The second effort is a financial modeling effort, from the 10 
perspective of the company, to assess whether the potential financial returns will 11 
justify the investments in developing the product. 12 
 13 
Value of the Grutters et al study 14 
The main value of the study by Grutter et al is that, since the analyses were performed 15 
by an independent organization, the findings could be placed in the public domain, 16 
following some restrictions to preserve confidential findings on the technologies 17 
concerned. This is important, since although much has been written about the 18 
potential value of early health economic modeling, there are few published examples 19 
of its impact or value. This is because the vast majority of analyses have been 20 
conducted in-house by technology manufacturers  (mainly pharmaceutical 21 
companies), where there is little need or incentive to make them public. The closest 22 
we see to actual examples relate to the preparatory work conducted by manufacturers 23 
WR VXSSRUW µHDUO\ HQJDJHPHQW¶ GLVFXVVLRQV ZLWK UHJXODWRUV DQG UHLPEXUVHPHQW24 
authorities (2). 25 
 26 
Issues for further discussion 27 
Although the paper by Grutters et al makes a strong case for the role of early health 28 
economic modeling, there are other issues meriting discussion, should we wish to 29 
assess how useful early modeling could be. The first issue relates to the question of 30 
go/ no-go decisions. It is correct to argue that if all the assessments conclude that a 31 
technology is cost-effective, it is hard to argue that it should be abandoned. But it is 32 
not clear how the assessments undertaken considered the price (or acquisition cost) of 33 
the technologies concerned. Some of the analyses conducted close to market access 34 
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presumably included a price, but it is not clear whether the analyses conducted in 1 
HDUOLHUVWDJHVRIGHYHORSPHQWDFFRXQWHGIRUWKHPDQXIDFWXUHU¶VSULFH expectations, or 2 
if any were even articulated. In the absence of inclusion of any price, or if price was 3 
varied in a sensitivity analysis, the modeling could still give the manufacturer an 4 
indication of whether particular price expectations could be met.  5 
The point is that, whatever the benefits in improved health and cost savings, any 6 
technology could be rejected on grounds of lacking cost-effectiveness if the 7 
PDQXIDFWXUHU¶V SULFH H[SHFWDWLRQV ZHUH WRR KLJK Ideally, the manuIDFWXUHU¶V SULFH8 
expectations would be set early on and revised upwards or downwards as more 9 
LQIRUPDWLRQDERXWWKHWHFKQRORJ\¶VSHUIRUPDQFH, or the need for additional research,  10 
becomes known. However, in most cases, decisions about price are usually discussed 11 
quite late in the development process, when arguably the decision might mainly be 12 
based on recovery of as many of the research and development costs as possible, 13 
rather than the level of profit that the technology is likely to make overall. Therefore, 14 
in order to best interpret the results of modeling, price expectations should be set 15 
earlier and reset periodically based on the acquisition of new information. 16 
Secondly, as Grutters et al note, early health economic modeling can be useful in 17 
guiding future research into the technology concerned. This is often because of the 18 
need to obtain more accurate estimates of the key parameters of the model, but could 19 
also be because the model indicates that there may be benefits from studying the 20 
technology in new patient populations or at a different position in the treatment 21 
pathway. 22 
Grutters et al are a little sceptical about whether probabilistic sensitivity analysis is 23 
the best way of characterizing uncertainty in situations where the quality of the 24 
information about the new technology is poor. Rather, they favour the use of 25 
deterministic sensitivity analysis. There is debate about this issue in the health 26 
economics literature, although one of the arguments in favour of a probabilistic 27 
approach is that it facilitates the use of formal value of information (VoI) analysis to 28 
guide future research. For example, VoI analysis can provide an estimate of the 29 
overall value of conducting more research to reduce decision uncertainty. It can also 30 
identify which model parameters it would most important to estimate more precisely. 31 
In addition, as Rothery et al (3) point out, VoI analysis provides the manufacturer 32 
with a formal approach for considering the trade-off, at different stages of 33 
development, between carrying out further research and revising price expectations 34 
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for the technology downwards. This links back to the point about pricing expectations 1 
made earlier. 2 
Thirdly, one of the interesting features of the paper by Grutters et al is that it 3 
demonstrates that early health economic modeling can be performed at different time 4 
points in the development of a technology. In the paper, the time points were 5 
determined by the timing of the requests for analyses E\WKHWHFKQRORJ\¶VVSonsor.  In 6 
two cases the analysis was performed twice, although it is not clear whether this was 7 
at different time points or not. However, in principle, early stage health economic 8 
modeling is not a µRQH-time¶ activity, but should be continuous and iterative, with the 9 
modeling being updated as more information becomes available, either about the 10 
technology itself or the environment in which it would be used (eg emergence of new 11 
technologies, changes in prices, etc.) (4) 12 
For example, the price of the existinJWHFKQRORJ\WKDWWKHPDQXIDFWXUHU¶VWHFKQRORJ\13 
seeks to replace, could fall, making the new technology less attractive. This happened 14 
with drug-eluting stents in the United Kingdom. The price of bare metal stents fell, 15 
causing the incremental cost-effectiveness of drug-eluting stents to rise above the 16 
acceptable threshold in the UK (5). Alternatively, a new competitor technology could 17 
emerge, or there could be a change in decision-PDNHUV¶UHTXLUHPHQWVIRUHYLGHQFHRQ18 
effectiveness or cost-effectiveness. 19 
 20 
Towards a comprehensive role for early stage modeling 21 
Grutters et al should be congratulated on an important contribution to the debate about 22 
the value of early health economic modeling. Based on their findings and the issues 23 
raised above, one could argue for a more comprehensive role for early stage health 24 
economic modeling. First, it would be iterative, with modeling being performed at 25 
multiple points in the development of the technology, normally at key points where 26 
either (i) an important decisions about the need for further research, or a change in 27 
positioning or pricing expectations needed to be made, or (ii) there was an important 28 
change in the external environment affecting the likely success or value of the 29 
technology. 30 
Secondly, the modeling effort would comprise three, interlinked efforts (i) cost-31 
effectiveness modeling from the perspective of the intended payer or reimbursement 32 
authority; (ii) modeling of the future research strategy for the technology, based on 33 
value of information analysis where possible and; (iii) financial modeling, of expected 34 
5 
 
research costs, technology price and revenue, from the perspective of the 1 
manufacturer.  2 
 3 
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